Navigation Links
Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
Date:5/24/2010

BEIJING, May 24 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical products in China, announced today an exclusive distributor agreement for HEYER Medical's Cumulus ultrasonic nebulizer in China. Dehaier is authorized to distribute all models of this product.

HEYER Cumulus is suitable for the treatment of respiratory tract conditions such as asthma, bronchitis, chronic respiratory infections and others. The unit can be used for all aspects of respiratory treatment and air humidification. With a full range of accessories, the Cumulus Nebulizer is tailored for optimum application in hospitals, surgeries and at home.

HEYER Cumulus is designed to be extremely easy to clean. All application parts and the ultrasonic cup can be dismantled in seconds. In addition, all parts (including the ultrasonic cup assembly) that may be subject to patient contamination can be easily disinfected or autoclaved.

Mr. Volker Muller, General Manager of HEYER Medical (Beijing) Ltd., said, "We are very pleased that Dehaier will represent HEYER products in China. Dehaier is a premier medical device company that has a powerful distribution network in China. We believe this exclusive distribution agreement is an excellent business expansion opportunity for both companies."

Mr. Ping Chen, Dehaier's Chief Executive Officer, said, "Our new partnership with HEYER Medical further supplements our product line for treatment of respiratory diseases. This not only provides Dehaier with additional highly sophisticated products, but also widens the experience of our marketing and service teams. This exclusive agreement provides us with access to the market segment in China for nebulizer products, which we estimate to be about $30 million per year. The Cumulus is an ideal product addition to our Homecare Medical Products segment that already includes homecare ventilators, oxygen generators, sleep screening systems and our Dehaier rhinitis hyperthermia device.

"We estimate that on a global basis, the fast growing market for respiratory and oxygen homecare products is in excess of $2.0 billion per year," Chen said.

About HEYER Medical AG

HEYER was founded in 1883 in Germany and has become an innovator in inhalation technology for the treatment of respiratory tract diseases. Today HEYER is an internationally acknowledged specialist in state-of-the-art inhalation and anesthesia medical equipment, oxygen concentrators, breathing therapy equipment and connecting equipment. HEYER products are used all over the world, particularly in the medical field, in clinics and practices in Europe and Asia as well as in the Middle East, South America and the USA. Our inhalation equipment is also increasingly used in wellness applications and for treatment and care at home. Website http://www.heyermedical.de

About Dehaier Medical Systems Ltd.

Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Timesco (UK), ResMed (Australia), Welch Allyn (USA), HEYER (Germany) and JMS (Japan). Dehaier's technology is based on two patents, five pending patents and proprietary technology. More information may be found at http://www.chinadhr.com .

Information for investors, including an investment profile about Dehaier is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at http://www.hawkassociates.com .

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    Investor contact:

     Hawk Associates
     Julie Marshall or Frank Hawkins
     Tel:   +1-305-451-1888
     Email: dehaier@hawkassociates.com


'/>"/>
SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017  Atrius ... Health today entered into an agreement to develop ... physician-patient experience. By providing a holistic view of ... social determinants, Watson Cognitive Insights could be designed ... patients. Atrius Health is an innovative nonprofit healthcare ...
(Date:2/18/2017)... , Feb 17, 2017 Research and ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... Europe , and Rest of World. Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today ... peptide drug candidates, PTG-100 and PTG-200, at the ... and Colitis Organization (ECCO).  The ECCO congress is ... from February 15 – 18, 2017. ... Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a ...
(Date:2/16/2017)... PALM BEACH, Fla. , Feb. 16, 2017 ... diagnostics company revolutionizing the development of liquid biopsy ... it has entered into an exclusive license agreement ... will distribute MDNA,s proprietary liquid biopsy test for ... South Korea . This is ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
(Date:1/18/2017)... 18, 2017 MedNet Solutions , ... the entire spectrum of clinical research, is proud ... year for the organization in terms of corporate ... eClinical products and services. The company,s exceptional achievements ... of iMedNet ™ ...
Breaking Biology News(10 mins):